Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: A case report and review of the literature

Journal of Drugs in Dermatology

Volumn 8, Issue 8, 2009, Pages 765-769

  Fabi, Sabrina Guillen ^a   Hill, Carlotta ^a   Witherspoon, Joslyn N ^b   Boone, Susan L ^b   West, Dennis P ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOFAZIMINE; DAPSONE; HEPARIN; PREDNISONE; RIFAMPICIN; THALIDOMIDE; WARFARIN; LEPROSTATIC AGENT;

ADULT; ANKLE PAIN; ARTHRALGIA; ARTICLE; CASE REPORT; COARSE FACE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; DRUG DOSE REDUCTION; DYSPNEA; ERYTHEMA NODOSUM LEPROSUM; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPESTHESIA; HYPOPIGMENTATION; INTERNATIONAL NORMALIZED RATIO; LEG EDEMA; LEG PAIN; LEPROMATOUS LEPROSY; LUNG EMBOLISM; MALAISE; MALE; MULTIBACILLARY LEPROSY; MYCOBACTERIUM LEPRAE; NONHUMAN; PERIPHERAL NEUROPATHY; PULMONARY ARTERY; SKIN BIOPSY; SKIN BURNING SENSATION; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; THORAX PAIN; WALKING DIFFICULTY; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; ERYTHEMA NODOSUM; REVIEW; VEIN THROMBOSIS;

ADULT; DRUG THERAPY, COMBINATION; ERYTHEMA NODOSUM; HUMANS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; PREDNISONE; PULMONARY EMBOLISM; THALIDOMIDE; VENOUS THROMBOSIS;

EID: 70349256406     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303-306.
2. Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid (thalidomide) capsules: A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf. 2001;24(2):87-117.
3. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001; 98(5):1614-1615.
4. Flageul B, Wallach D, Cavelier-Balloy B, et al. Thalidomide and thrombosis. Ann Dermatol Venereol. 2000;127(2):171-174. (Pubitemid 30182847)
5. Howell E, Johnson SM. Venous thrombosis occurring after initiation of thalidomide for the treatment of cicatricial pemphigoid. J Drugs Dermatol. 2004;3(1):83-85.
6. Gachon J, Grob JJ, Richard MA. Thrombotic accidents induced by thalidomide: Two cases. Rev Med Interne. 2002;23(8):724-727. (Pubitemid 35014463)
7. Nguyen YT, Dupuy A, Cordoliani F, et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol. 2004;50:235-241. (Pubitemid 38174281)
8. Sharma N, Sharma V, Shanker V, et al. Deep vein thrombosis: A rare complication of thalidomide therapy in recurrent erythema nodosum leprosum. Int J Lepr Other Mycobact Dis. 2004;72(4):483-485. (Pubitemid 40179985)
9. Radomsky CL, Levine N. Thalidomide. Dermatol Clin. 2001;19(1):87-103. (Pubitemid 32038048)
10. Matthews SJ, McCoy C. Thalidomide: A review of approved and investigational uses. Clin Ther. 2003;25(2):342-395. (Pubitemid 36286909)
11. Osman K, Comenzo R, Rajkumar SV. DVT and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344:1951-1952. (Pubitemid 32553371)
12. Sharma NL, Sharma VC, Mahajan VK, et al. Thalidomide: An experience in therapeutic outcome and adverse reactions. J Dermatolog Treat. 2007;18(6):35-40.
13. Kaushal V, Kohli M, Zangari M, et al. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol. 2002;20(13):3042.
14. Angelotta, C and Bennett CL. Thalidomide- and lenalidomide-associated thromboembolism. Commun Oncol. 2007;4:147-148. (Pubitemid 46569676)
15. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide-and lenalidomide-associated thromboembolism among patients with cancer. J Am Med Assoc. 2006;296(21):2558-2560. (Pubitemid 44903859)
16. Bennett CI, Nebeker JR, Lyons EA, et al. The research on adverse drug events and reports (RADAR) Project. J Am Med Assoc. 2005;293:2131-2140. (Pubitemid 40617066)
17. U.S. Food and Drug Administration Web site. Thalidomide package insert. http://www.fda.gov/cder/foi/label/2006/021430s000,020785s031lbl.pdf. Accessed February 22, 2008.
18. U.S. Food and Drug Administration Web site. Lenalidomide package insert. http://www.fda.gov/medwatch/safety/2006/Jun-PIs/Revlimid-PI.pdf. Accessed February 22, 2008.
19. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-505. (Pubitemid 350232226)
20. Palumbo A, Rajkumar SV, Dimopoulous MA, et al. Prevention of thalidomide and lenalidomide associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423. (Pubitemid 351255436)
21. Niesvizky R, Martínez-Baños D, Jalbrzikowski J, et al. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma. 2007;48(12):2330-2337. (Pubitemid 350253464)
22. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80(12):1568-1574. (Pubitemid 41747058)
23. Minnema MC, Breitkreutz I, Auwerda JJ, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004;18(12):2044-2046. (Pubitemid 40028434)
24. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004;5(5):715-721. (Pubitemid 39221309)